GlassScriptPhysician profile
William T Stephenson
NPI 1093787541
$4,786.07
in general payments reported to CMS, 2019-2025
47 companies · $2,311 in 2025
The $2,311 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.04 · 2021: $24.15 · 2022: $164 · 2023: $417 · 2024: $1,818 · 2025: $2,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,519 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,519.28 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $465.48 | 2022-2025 | |
| Daiichi Sankyo INC. | $399.89 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $364.49 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $307.12 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $255.17 | 2022-2025 | |
| Abbvie INC. | $249.77 | 2019-2025 | |
| Janssen Biotech, INC. | $237.61 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $233.02 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $213.46 | 2023-2025 | Opdivo, Krazati, Opdualag |
| Celgene Corporation | $156.05 | 2022-2024 | Reblozyl, Pomalyst |
| Genzyme Corporation | $144.61 | 2019-2025 | |
| Emd Serono, INC. | $129.89 | 2024-2025 | |
| Tempus Ai, INC | $121.45 | 2024-2025 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $108.17 | 2023-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $91.95 | 2024-2025 | Fruzaqla, Iclusig |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $91.52 | 2021-2025 | Monjuvi, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $78.18 | 2024-2025 | |
| Genmab U.S., INC. | $78.13 | 2024-2025 | Tivdak, Epkinly |
| Tersera Therapeutics LLC | $77.47 | 2023-2025 | Zoladex, Xermelo |
| Agios Pharmaceuticals, INC. | $75.19 | 2023-2025 | Pyrukynd |
| Puma Biotechnology, INC. | $67.81 | 2024-2025 | |
| Genentech USA, INC. | $67.32 | 2019-2024 | Venclexta |
| Array Biopharma INC | $62.02 | 2025 | Braftovi, Lorbrena, Mektovi |
| Gilead Sciences, INC. | $53.95 | 2021-2024 | |
| Astellas Pharma US INC | $50.56 | 2025 | Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $46.06 | 2023 | Imbruvica |
| Beone Medicines USA, INC. | $44.36 | 2025 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $42.51 | 2025 | |
| Pharmacosmos Therapeutics INC. | $39.32 | 2023-2025 | Monoferric |
| Springworks Therapeutics, INC. | $39.12 | 2024-2025 | Ogsiveo |
| Lilly USA, LLC | $38.40 | 2024 | Verzenio, Retevmo, Jaypirca |
| Legend Biotech USA INC. | $37.96 | 2025 | Carvykti |
| Beigene USA, INC. | $33.43 | 2024 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $28.69 | 2025 | Revuforj |
| Accord Healthcare, INC. | $24.45 | 2024 | |
| Geron Corporation | $24.40 | 2025 | Rytelo |
| Amgen INC. | $22.43 | 2022 | |
| Sumitomo Pharma America, INC. | $21.97 | 2025 | Orgovyx |
| Karyopharm Therapeutics INC. | $21.85 | 2024 | Xpovio |
| Azurity Pharmaceuticals, INC. | $21.35 | 2025 | Danziten |
| Eisai INC. | $20.52 | 2025 | |
| Aveo Pharmaceuticals, INC. | $20.23 | 2024 | |
| Deciphera Pharmaceuticals INC. | $18.56 | 2023 | Qinlock |
| Fresenius Kabi USA, LLC | $16.74 | 2025 | |
| Novocure INC. | $15.83 | 2025 | Optune Lua (Novottf-200t) |
| Rigel Pharmaceuticals, INC. | $14.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.